Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
butyrate enemas will be administered for 12 weeks to children ages 7 to 21 with mild to moderate ulcerative colitis to determine if butyrate therapy can help improve the clinical disease in those children. standard management of the disease will be performed during these 12 weeks including routine laboratory studies and endoscopy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Butyrate enemas will be administered once a day for 12 weeks
Children's Hospital Los Angeles
Los Angeles, California, United States
RECRUITINGNumber of participants that experience pediatric ulcerative colitis activity index score <10.
pediatric ulcerative colitis activity index, remission is \<10, mild disease 10-34, moderate 35-64, severe 65 or greater
Time frame: 12 weeks
Number of participants with improvement to inflammatory markers using ESR, CRP, and Calprotectin
normalization or at least improvement of inflammatory markers described above
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.